Francoise Bodere-Kraeber

Head And Neck
Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 159 publications

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 25, 2026

CXCR4-Targeted Molecular Imaging in Hematology and Oncology.

CXCR4-Targeted Molecular Imaging in Hematology and Oncology.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 22, 2026

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

Journal: Blood

Published: February 19, 2026

Bimodal PET/CT and PET/MRI imaging in multiple myeloma/prostate cancer restaging and response to BCMA-targeted CAR T-therapy assessment.

Bimodal PET/CT and PET/MRI imaging in multiple myeloma/prostate cancer restaging and response to BCMA-targeted CAR T-therapy assessment.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 10, 2026

[18F]F-DOPA and [18F]F-FDG-PET/CT for staging advanced medullary thyroid cancer.

[18F]F-DOPA and [18F]F-FDG-PET/CT for staging advanced medullary thyroid cancer.

Journal: Annales d'endocrinologie

Published: February 08, 2026

Optimal acquisition time of [68Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol.

Optimal acquisition time of [68Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol.

Journal: EJNMMI research

Published: January 08, 2026

FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Journal: Blood advances

Published: December 22, 2025

Prognostic Value of Cranial Arteries Involvement on 18 F-FDG PET/CT at Giant Cell Arteritis Diagnosis in a Multicenter Cohort.

Prognostic Value of Cranial Arteries Involvement on 18 F-FDG PET/CT at Giant Cell Arteritis Diagnosis in a Multicenter Cohort.

Journal: Clinical nuclear medicine

Published: December 03, 2025

Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE).

Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE).

Journal: European journal of nuclear medicine and molecular imaging

Published: July 10, 2025

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.

Journal: Blood

Published: May 21, 2025

Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact.

Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact.

Journal: Leukemia

Published: April 29, 2025

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Journal: Blood advances

Published: December 10, 2024

Showing 1-12 of 159

Last Updated: 09/26/2026